ADDvise Group contemplates issuance of subsequent senior secured bonds

21-11-2022   Regulatory press release

ADDvise Group AB (publ) has mandated Pareto Securities AB to arrange a series of fixed income investor meetings starting on 22 November 2022. Subject to inter alia market conditions, a subsequent bond issue of SEK 150 million under the company's existing senior secured bond loan with ISIN SE0015222088 (the "Bonds") may follow. The subsequent bond issue is fully subscribed based on substantial pre-commitments and indications from certain investors.

The net proceeds from the contemplated subsequent bond issue will be used to part-finance the acquisition of CliniChain Holding B.V. or any other acquisition replacing the acquisition of CliniChain Holding B.V.

In connection with the contemplated subsequent bond issue, the company will request approval from holders of the Bonds for certain amendments to the terms and conditions of the Bonds in order to inter alia permit the contemplated subsequent bond issue. Additional information pertaining to the written procedure is set out in a separate press release as well as in the relevant notice of written procedure.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Hanna Myhrman, General Counsel
+46 709-82 92 23
hanna.myhrman@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 21 November 2022 at 17:45 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business – both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

 

 

 

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected

Regulatory

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million

Regulatory

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…